

AMGEN INC  
Form S-8  
March 15, 2017

As filed with the Securities and Exchange Commission on March 15, 2017

Registration No. 333-

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**AMGEN INC.**

**(Exact Name of Registrant as Specified in Its Charter)**

**Delaware**  
**(State or Other Jurisdiction of**

**Incorporation or Organization)**

**One Amgen Center Drive**

**Thousand Oaks, California 91320-1799**

**95-3540776**  
**(IRS Employer**

**Identification Number)**

**(805) 447-1000**

**(Address of Principal Executive Offices including Zip Code)**

**Amgen Nonqualified Deferred Compensation Plan**

**(Full Title of the Plan)**

*Copy to:*

**Jonathan P. Graham, Esq.**

**Charles K. Ruck, Esq.**

**Senior Vice President, General Counsel and Secretary**

**Regina Schlatter, Esq.**

**One Amgen Center Drive**

**Latham & Watkins LLP**

**Thousand Oaks, California 91320-1799**

**650 Town Center Drive, Twentieth Floor  
Costa Mesa, California 92626-1925**

**(714) 540-1235**

**(805) 447-1000**

**(Name and Address, Including Zip Code and Telephone Number, Including Area Code, of Agent for Service)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer or a smaller reporting company in Rule 12-b2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if smaller reporting company.)

Smaller reporting company

**CALCULATION OF REGISTRATION FEE**

<b>Title of Securities to be Registered</b>	<b>Amount to be Registered</b>	<b>Proposed Maximum Offering Price Per Share</b>	<b>Proposed Maximum Aggregate Offering Price</b>	<b>Amount of Registration Fee(2)</b>
Deferred Compensation Obligations (1)	\$200,000,000	N/A	\$200,000,000	\$23,180

- (1) The deferred compensation obligations to which this Registration Statement relates (the Deferred Compensation Obligations ) arise under the Amgen Nonqualified Deferred Compensation Plan, as Amended and Restated Effective October 16, 2013, as subsequently amended (the Plan ) and are unsecured obligations of the Registrant to pay deferred compensation in the future in accordance with the terms of the Plan.
- (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act of 1933, as amended (the Securities Act ), the amount of deferred compensation obligations registered is based on an estimate of the amount of compensation that may be deferred under the Plan.

## INTRODUCTION

### REGISTRATION OF ADDITIONAL SECURITIES

This registration statement on Form S-8 (the Registration Statement ) is filed by Amgen Inc. (referred to herein as our, we, us or the Registrant ) relating to \$200,000,000 deferred compensation obligations which are unsecured obligations of the Registrant to pay deferred compensation in the future in accordance with the terms of the Plan. Pursuant to General Instructions E to Form S-8, the contents of the Registrant's Form S-8 Registration Statement previously filed with the Securities and Exchange Commission (the Commission ) on November 9, 2011 (File No. 333-177868), registering \$200,000,000 deferred compensation obligations under the Plan, are herein incorporated by reference to the extent not modified or superseded hereby or by any subsequently filed document that is incorporated by reference herein or therein.

### PART I

#### INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

We are not filing with or including in this Form S-8 the information called for in Part I of Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Commission.

### PART II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

**Item 8. Exhibits**

See Index to Exhibits on page 5.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Thousand Oaks, State of California, on the 15<sup>th</sup> day of March, 2017.

AMGEN INC.

By:

/s/ Robert A. Bradway

Robert A. Bradway

Chairman of the Board, Chief Executive  
Officer and President

**POWER OF ATTORNEY**

KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert A. Bradway, David W. Meline and Jonathan P. Graham, or any of them, his or her attorney-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ Robert A. Bradway	Chairman of the Board, Chief Executive Officer and President	March 15, 2017
<b>Robert A. Bradway</b>	(Principal Executive Officer)	
/s/ David W. Meline	Chief Financial Officer	March 15, 2017
<b>David W. Meline</b>	(Principal Financial Officer)	
/s/ Annette L. Such	Vice President, Finance and Chief Accounting Officer	March 15, 2017
<b>Annette L. Such</b>	(Principal Accounting Officer)	
/s/ David Baltimore	Director	March 15, 2017

**David Baltimore**

/s/ Frank J. Biondi, Jr.

Director

March 15, 2017

**Frank J. Biondi, Jr.**

/s/ François de Carbonnel

Director

March 15, 2017

**François de Carbonnel**

---

/s/ Robert A. Eckert	Director	March 15, 2017
<b>Robert A. Eckert</b>		
/s/ Greg C. Garland	Director	March 15, 2017
<b>Greg C. Garland</b>		
/s/ Fred Hassan	Director	March 15, 2017
<b>Fred Hassan</b>		
/s/ Rebecca M. Henderson	Director	March 15, 2017
<b>Rebecca M. Henderson</b>		
/s/ Frank C. Herringer	Director	March 15, 2017
<b>Frank C. Herringer</b>		
/s/ Tyler Jacks	Director	March 15, 2017
<b>Tyler Jacks</b>		
/s/ Ellen J. Kullman	Director	March 15, 2017
<b>Ellen J. Kullman</b>		
/s/ Judith C. Pelham	Director	March 15, 2017
<b>Judith C. Pelham</b>		
/s/ Ronald D. Sugar	Director	March 15, 2017
<b>Ronald D. Sugar</b>		
/s/ R. Sanders Williams	Director	March 15, 2017
<b>R. Sanders Williams</b>		

**INDEX TO EXHIBITS**

<b>NUMBER</b>	<b>DESCRIPTION</b>
5.1*	Opinion of Latham & Watkins LLP
23.1*	Consent of Independent Registered Public Accounting Firm.
23.2*	Consent of Latham & Watkins LLP (included in Exhibit 5.1).
24.1*	Power of Attorney (included on signature page to Registration Statement).
99.1	Amgen Nonqualified Deferred Compensation Plan, as Amended and Restated Effective October 16, 2013. (Filed as an exhibit to Form 10-K for the year ended December 31, 2013, on February 24, 2014 and incorporated herein by reference.)
99.2	First Amendment to the Amgen Non Nonqualified Deferred Compensation Plan, effective October 14, 2016. (Filed as an exhibit 10.17 to Form 10-Q for the quarter ended September 30, 2016, on October 28, 2016 and incorporated herein by reference.)

\* Filed herewith.